<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754635</url>
  </required_header>
  <id_info>
    <org_study_id>00126-15-EMC</org_study_id>
    <nct_id>NCT02754635</nct_id>
  </id_info>
  <brief_title>Induction Versus Expectant Management With Abnormal Maternal Biochemical Markers</brief_title>
  <official_title>Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of labor at term versus expectant management among women with abnormal maternal
      biochemical markers. A randomized controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnancy-associated plasma protein A (PAPP-A), alpha-fetoprotein (AFP), human chorionic
      gonadotropin (hCG), and inhibin A, are biochemical markers that are part of the first and
      second trimester screening test, for Down syndrome and neural tube defects in pregnancy.
      These biochemical markers have been shown also to be associated with slightly increased risk
      for adverse pregnancy outcomes in the absence of aneuploidy or neural tube defects, for
      example; preeclampsia, low birth weight, placental abruption, preterm labor, and intrauterine
      fetal death.

      There are no guidelines regarding the management of these cases assuming a reassuring
      maternal and fetal status are normal, at term (38 - 39 weeks). However, adverse events may
      still develop between 38 to 42 weeks when calculated according to ongoing pregnancy.

      Investigators aim in this randomized trial to examine the effect of induction of labor at 38
      - 39 weeks compared to expectant management among women with abnormal first or second
      biochemical screening tests on maternal and perinatal outcomes.

      Enrollment: 320 women in both groups. Interim analyses will be performed after enrolling 50%
      of the participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placental abruption</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical diagnosis. Co-primary endpoint #1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gestational hypertension</measure>
    <time_frame>4 weeks</time_frame>
    <description>Blood pressure above 140/90 mmHg. Co-primary endpoint #2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Small of gestational age</measure>
    <time_frame>4 weeks</time_frame>
    <description>Birth Weight less than the 10th percentile. Co-primary endpoint #3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-uterine death</measure>
    <time_frame>4 weeks</time_frame>
    <description>Fetal death. Co-primary endpoint #4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>4 weeks</time_frame>
    <description>vaginal or cesarean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrapartum fever</measure>
    <time_frame>4 weeks</time_frame>
    <description>fever above 38C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Apgar score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>PREGNANCY</condition>
  <arm_group>
    <arm_group_label>Induction of labour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction of labour at 38-39 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expectant management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Expectant management until 41 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Induction of labour</intervention_name>
    <description>Induction of labour</description>
    <arm_group_label>Induction of labour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Expectant management</intervention_name>
    <description>Expectant management</description>
    <arm_group_label>Expectant management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCG, AFP or Inhibin greater than 2 multiple of median (MOM) or PAPPA less than 0.15
             MOM.

          -  Singleton.

          -  Appropriate for gestational age fetus.

          -  Reassuring fetal status including normal amniotic fluid index.

        Exclusion Criteria:

          -  Any hypertensive disorder.

          -  Indication for induction of labour at enrollment.

          -  Any contraindication of induction of labour.

          -  Prior cesarean delivery.

          -  Any contraindication for a trial of vaginal delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raed Salim</last_name>
    <role>Study Chair</role>
    <affiliation>Emek Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emek medical center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raed Salim, MD</last_name>
      <phone>97246494031</phone>
      <email>salim_ra@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Manal Massalha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Yuan W, Chen L, Bernal AL. Is elevated maternal serum alpha-fetoprotein in the second trimester of pregnancy associated with increased preterm birth risk? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2009 Jul;145(1):57-64. doi: 10.1016/j.ejogrb.2009.04.017. Epub 2009 May 19. Review.</citation>
    <PMID>19457604</PMID>
  </results_reference>
  <results_reference>
    <citation>Ganapathy R, Lamont RF, Bassett P. Unexplained elevated maternal serum beta-HCG concentration and adverse pregnancy outcome. Prenat Diagn. 2007 Nov;27(11):995-9.</citation>
    <PMID>17621365</PMID>
  </results_reference>
  <results_reference>
    <citation>Alkazaleh F, Chaddha V, Viero S, Malik A, Anastasiades C, Sroka H, Chitayat D, Toi A, Windrim RC, Kingdom JC. Second-trimester prediction of severe placental complications in women with combined elevations in alpha-fetoprotein and human chorionic gonadotrophin. Am J Obstet Gynecol. 2006 Mar;194(3):821-7.</citation>
    <PMID>16522419</PMID>
  </results_reference>
  <results_reference>
    <citation>Gagnon A, Wilson RD; SOCIETY OF OBSTETRICIANS AND GYNAECOLOGISTS OF CANADA GENETICS COMMITTEE. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008 Oct;30(10):918-932. doi: 10.1016/S1701-2163(16)32973-5. Review. English, French.</citation>
    <PMID>19038077</PMID>
  </results_reference>
  <results_reference>
    <citation>Luckas MJ, Sandland R, Hawe J, Neilson JP, McFadyen IR, Meekins JW. Fetal growth retardation and second trimester maternal serum human chorionic gonadotrophin levels. Placenta. 1998 Mar-Apr;19(2-3):143-7.</citation>
    <PMID>9548180</PMID>
  </results_reference>
  <results_reference>
    <citation>Wax JR, Lopes AM, Benn PA, Lerer T, Steinfeld JD, Ingardia CJ. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome. J Matern Fetal Med. 2000 May-Jun;9(3):161-4.</citation>
    <PMID>10914623</PMID>
  </results_reference>
  <results_reference>
    <citation>Salim R, Okopnik M, Garmi G, Nachum Z, Zafran N, Shalev E. Lack of association between unexplained elevated maternal serum alpha fetoprotein and/or human chorionic gonadotropin and the occurrence of placental thrombotic lesions. Placenta. 2010 Apr;31(4):277-81. doi: 10.1016/j.placenta.2010.01.010. Epub 2010 Feb 4.</citation>
    <PMID>20132984</PMID>
  </results_reference>
  <results_reference>
    <citation>Saruhan Z, Ozekinci M, Simsek M, Mendilcioglu I. Association of first trimester low PAPP-A levels with adverse pregnancy outcomes. Clin Exp Obstet Gynecol. 2012;39(2):225-8.</citation>
    <PMID>22905470</PMID>
  </results_reference>
  <results_reference>
    <citation>Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME; FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005 Aug;106(2):260-7.</citation>
    <PMID>16055573</PMID>
  </results_reference>
  <results_reference>
    <citation>Caughey AB, Stotland NE, Escobar GJ. What is the best measure of maternal complications of term pregnancy: ongoing pregnancies or pregnancies delivered? Am J Obstet Gynecol. 2003 Oct;189(4):1047-52.</citation>
    <PMID>14586353</PMID>
  </results_reference>
  <results_reference>
    <citation>Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol. 2007 Aug;31(4):208-12. Review.</citation>
    <PMID>17825674</PMID>
  </results_reference>
  <results_reference>
    <citation>Konchak PS, Bernstein IM, Capeless EL. Uterine artery Doppler velocimetry in the detection of adverse obstetric outcomes in women with unexplained elevated maternal serum alpha-fetoprotein levels. Am J Obstet Gynecol. 1995 Oct;173(4):1115-9.</citation>
    <PMID>7485303</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>August 13, 2017</last_update_submitted>
  <last_update_submitted_qc>August 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Manal Massalha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Abnormal first or second trimester biochemical markers</keyword>
  <keyword>maternal and perinatal morbidity/mortality</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

